Skip to main content
OpenTrials

Clinical trial condition

Sleep Disorders, Intrinsic

Explore clinical trials studying Sleep Disorders, Intrinsic. Study availability and eligibility vary by location and protocol.

4,492 public trials 665 recruiting studies
Refine in advanced search Browse all conditions

Sleep Disorders, Intrinsic trial results

Completed

Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs Syndrome

NCT00144209

Conditions
Dyssomnias, Mental Disorders, Nervous System Diseases, +4 more
Locations
  • Boehringer Ingelheim Investigational Site Bad Zurzach, Switzerland
  • Boehringer Ingelheim Investigational Site Basel, Switzerland
  • Boehringer Ingelheim Investigational Site Basel, Switzerland
  • Boehringer Ingelheim Investigational Site Bern, Switzerland
View Trial Details
Completed

Non-interventional Observational Study of Pramipexole in Restless Legs Syndrome: Impact on Quality of Life

NCT00539461

Conditions
Dyssomnias, Mental Disorders, Nervous System Diseases, +4 more
Locations
  • Boehringer Ingelheim Investigational Site Aalen, Germany
  • Boehringer Ingelheim Investigational Site Aarbergen, Germany
  • Boehringer Ingelheim Investigational Site Adendorf, Germany
  • Boehringer Ingelheim Investigational Site Aham, Germany
View all 317 locations
View Trial Details
Completed

Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) Patients

NCT00275457

Conditions
Dyssomnias, Mental Disorders, Nervous System Diseases, +4 more
Locations
  • Univ.-Klinik für Neurologie Graz, Austria
  • Univ.-Klinik für Neurologie Innsbruck, Austria
  • AKH der Stadt Linz Linz, Austria
  • Confraternität Privatklinik Vienna, Austria
View all 34 locations
View Trial Details
Completed

Pramipexole (BI-Sifrol®) Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome

NCT00152997

Conditions
Dyssomnias, Mental Disorders, Nervous System Diseases, +4 more
Locations
  • Boehringer Ingelheim Investigational Site Akita, Akita, Japan
  • Boehringer Ingelheim Investigational Site Kochi, Kochi, Japan
  • Boehringer Ingelheim Investigational Site Kurume, Fukuoka, Japan
  • Boehringer Ingelheim Investigational Site Otaru,Hokkaido, Japan
View Trial Details
Completed

A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS

NCT00375284

Conditions
Dyssomnias, Mental Disorders, Nervous System Diseases, +4 more
Locations
  • 248.616.065 Boehringer Ingelheim Investigational Site Birmingham, Alabama, United States
  • 248.616.028 Boehringer Ingelheim Investigational Site Dothan, Alabama, United States
  • 248.616.035 Boehringer Ingelheim Investigational Site Mesa, Arizona, United States
  • 248.616.025 Boehringer Ingelheim Investigational Site Peoria, Arizona, United States
View all 52 locations
View Trial Details

Related conditions